Open AccessAlefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients
Author(s) -
Mark R. Rigby,
Kristina M. Harris,
Ashley Pinckney,
Linda A. DiMeglio,
Marc Rendell,
Eric I. Felner,
Jean M. Dostou,
Stephen E. Gitelman,
Kurt Griffin,
Eva Tsalikian,
Peter Gottlieb,
Carla J. Greenbaum,
Nicole Sherry,
Wayne V. Moore,
Roshanak Monzavi,
Steven M. Willi,
Philip Raskin,
Lynette Keyes-Elstein,
S. Alice Long,
Sai Kanaparthi,
Noha Lim,
Deborah Phippard,
Carol L. Soppe,
Margret L. Fitzgibbon,
James O McNamara,
Gerald T. Nepom,
Mario R. Ehlers
Publication year - 2015
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/0rtj-8b69
Subject(s) - type 2 diabetes , medicine , diabetes mellitus , type 1 diabetes , immunology , endocrinology